Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Correspondence (2)
  7. Conference Paper (1)
Groups
  1. Department of Medicine (292)
  2. Solid Tumor Oncology Division (292)
  3. Thoracic Oncology (292)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (105)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (21)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (85)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay
    Meeting Abstract

    Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping
    Journal Article

    Paik, P. K.; Drilon, A.; Fan, P. D.; Yu, H.; Rekhtman, N.; Ginsberg, M. S.; Borsu, L.; Schultz, N.; Berger, M. F.; Rudin, C. M.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • Phase I/II study of HSP90 inhibitor AUY922 and Erlotinib for EGFR-Mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Journal Article

    Johnson, M. L.; Yu, H. A.; Hart, E. M.; Weitner, B. B.; Rademaker, A. W.; Patel, J. D.; Kris, M. G.; Riely, G. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas
    Journal Article

    Yu, H. A.; Sima, C. S.; Hellmann, M. D.; Naidoo, J.; Busby, N.; Rodriguez, K.; Riely, G. J.; Kris, M. G.
    Cancer (2015)

    Fulltext@MSK | Save
  • Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas
    Journal Article

    Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S.; Gainor, J.; Shaw, A.; Hames, M.; Iams, W.; Aston, J.; Lovly, C. M.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive assessment of targetable driver alterations in lung adenocarcinomas using a clinical, hybrid capture-based, next-generation sequencing assay
    Meeting Abstract

    Arcila, M.; Zehir, A.; Cheng, D.; Yu, H.; Kris, M.; Drilon, A.; Riely, G.; Berger, M.; Ladanyi, M.
    Modern Pathology (2015)

    Fulltext@MSK | Save
  • Comprehensive assessment of targetable driver alterations in lung adenocarcinomas using a clinical, hybrid capture-based, next-generation sequencing assay
    Meeting Abstract

    Arcila, M.; Zehir, A.; Cheng, D.; Yu, H.; Kris, M.; Drilon, A.; Riely, G.; Berger, M.; Ladanyi, M.
    Laboratory Investigation (2015)

    Fulltext@MSK | Save
  • Stage at diagnosis as a prognostic marker for patients with KRAS-mutant metastatic lung adenocarcinomas
    Meeting Abstract

    Yu, H. A.; Hellmann, M. D.; Sima, C. S.; Busby, N.; Rodriguez, K.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Concurrent molecular alterations in KRAS-mutant lung adenocarcinomas and effects on overall survival
    Meeting Abstract

    Riely, G. J.; Eng, J.; Yu, H. A.; Hsu, M.; Kris, M. G.; Borsu, L.; Cavatore, M.; Yannes, A.; Brzostowski, E.; Casanova, J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in patients with oncogene-driven lung adenocarcinomas
    Meeting Abstract

    Eng, J.; Hellmann, M. D.; Woo, K.; Sima, C. S.; Yu, H. A.; Arcila, M. E.; Ladanyi, M.; Kris, M. G.; Drilon, A. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save